EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID

Nicolette Frank, Douglas Dickinson iD, William Garcia, Yutao Liu iD, Hongfang Yu, Jingwen Cai iD, Sahaj Patel, Bo Yao, Xiaocui Jiang, Stephen Hsu

Viruses · 2024

DOI: 10.3390/v16020196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Nicolette Frank und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Biology & Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCD NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A recent estimate indicates that up to 23.7 million Americans suffer from long COVID, and approximately one million workers may be out of the workforce each day due to associated symptoms, leading to a USD 50 billion annual loss of salary. Post-COVID (Long COVID) neurologic symptoms are due to the initial robust replication of SARS-CoV-2 in the nasal neuroepithelial cells, leading to inflammation of the olfactory epithelium (OE) and the central nervous system (CNS), and the OE becoming a persistent infection site. Previously, our group showed that Epigallocatechin-3-gallate-palmitate (EC16) nanoformulations possess strong antiviral activity against human coronavirus, suggesting this green tea-derived compound in nanoparticle formulations could be developed as an intranasally delivered new drug to eliminate the persistent SARS-CoV-2 infection, leading to restored olfactory function and reduced inflammation in the CNS. The objective of the current study was to determine the compatibility of the nanoformulations with human nasal primary epithelial cells (HNpECs).

Methods

Nanoparticle size was measured using the ZetaView Nanoparticle Tracking Analysis (NTA) system; contact antiviral activity was determined by TCID50 assay for cytopathic effect on MRC-5 cells; post-infection inhibition activity was determined in HNpECs; and cytotoxicity for these cells was determined using an MTT assay. The rapid inactivation of OC43 (a β-coronavirus) and 229E (α-coronavirus) viruses was further characterized by transmission electron microscopy.

Results

A saline-based nanoformulation containing 0.1% w/v EC16 was able to inactivate 99.9999% β-coronavirus OC43 on direct contact within 1 min. After a 10-min incubation of infected HNpECs with a formulation containing drug-grade EC16 (EGCG-4′ mono-palmitate or EC16m), OC43 viral replication was inhibited by 99%. In addition, all nanoformulations tested for their effect on cell viability were comparable to normal saline, a regularly used nasal irrigation solution. A 1-min incubation of an EC16 nanoformulation with either OC43 or 229E showed an altered viral structure.

Conclusion

Nanoformulations containing EC16 showed properties compatible with nasal application to rapidly inactivate SARS-CoV-2 residing in the olfactory mucosa and to reduce inflammation in the CNS, pending additional formulation and safety studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansUnited StatesSARS-CoV-2Post-Acute COVID-19 SyndromeAntiviral AgentsFeasibility StudiesSaline SolutionInflammationLipidsCatechin

Stichwörter der Autor:innen

COVID-19EC16EGCG-palmitateLong COVIDnanoformulations

Substanzen

Antiviral Agentsepigallocatechin gallateSaline SolutionLipidsCatechin

Autor:innen und Institutionen

  • Department of Oral Biology & Diagnostic Sciences, Augusta University, Augusta, GA 30912, USA.
  • Camellix Research Laboratory, Augusta, GA 30912, USA.
  • Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA 30912, USA.
  • Changxing Sanju Biotech Co., Ltd., Hangzhou 310013, China.

ORCID-Profile: Douglas Dickinson, Yutao Liu, Jingwen Cai

Förderung

  • NIDCD NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Frank, N., Dickinson, D., Garcia, W., Liu, Y., Yu, H., Cai, J., Patel, S., Yao, B., Jiang, X., & Hsu, S. (2024). Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID. Viruses. https://doi.org/10.3390/v16020196

Vancouver

Frank N, Dickinson D, Garcia W, Liu Y, Yu H, Cai J, et al. Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID. Viruses. 2024. doi:10.3390/v16020196

BibTeX
@article{Frank2024,
  author = {Frank, Nicolette and Dickinson, Douglas and Garcia, William and Liu, Yutao and Yu, Hongfang and Cai, Jingwen and Patel, Sahaj and Yao, Bo and Jiang, Xiaocui and Hsu, Stephen},
  title = {Feasibility Study of Developing a Saline-Based Antiviral Nanoformulation Containing Lipid-Soluble EGCG: A Potential Nasal Drug to Treat Long COVID},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16020196}
}
Kostenlos starten →